gynecological oncology |
||||||
|
News for 18-Sep-25 Source: MedicineNet Diabetes General Source: MedicineNet Asthma General Source: MedicineNet Asthma General Source: MedicineNet Asthma General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Asthma General Source: MedicineNet Asthma General
|
The Best gynecological oncology websiteAll the gynecological oncology information you need to know about is right
here. Presented and researched by http://www.medical-mailings.com. We've searched
the information super highway far and wide to provide you with the
best gynecological oncology site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
gynecological oncology
Passion -- OK, I know you have heard this before but if you really care about gynecological oncology then you want to be sure you get the highest value for your money. There are numerous sites dealing with gynecological oncology and some may or may not have anything to teach you. That will not happen here. We are here to really stimulate your passion and make sure you get just what you need. It all starts with something you know and love and that is gynecological oncology. Please don't say a word. Just listen. And remember, don't share this with anyone. This is just between us. This is the single best source of finding the very best gynecological oncology information on the Internet. gynecological oncology
Corporate news or equity market information on gynecological oncology companies will be found at websites of brokers or share traders. Articles of this kind can give you a different perspective on gynecological oncology which enable you to identify solid, growing gynecological oncology organizations compared to fly-by-night operators. It may surprise you to learn that gynecological oncology companies will happily add you to their press release circulation list so that you can keep right up to date with developments in the field of gynecological oncology including new gynecological oncology products which may be of particular interest to consumers like yourself. -Saving Pediatric Drug Becomes Readily Available to Those in Need by: ARA Content
(ARA) - We can all sympathize with the frustration people experience waiting for a new drug that is being tested for a certain disorder. Imagine you have a child with a rare disorder and the only drug effective for treating the disorder is not only extremely hard to obtain, but available only through a nationally-administered random selection process. For many American families, this dilemma is a harsh reality. Patients suffering from a host of difficult to treat orphan disorders have found marked relief from using HP Acthar Gel. Some disorders Acthar helps include seizure complex in babies and young children, referred to as West's syndrome or infantile spasm; Still's disease and ulcerative colitis; Bell's palsy; multiple sclerosis; adrenocortical insufficiency and non-endocrine disorders that are responsive to glucocorticoids. For the past four years, however, the drug has only been available through a limited access program administered by the National Organization for Rare Disorders (NORD), a federation of more that 135 non-profit health organizations serving people with rare disorders. U.S. physicians who were interested in obtaining Acthar Gel for their patients with life-threatening or severely debilitating conditions who did not respond to any other treatment were given first access to the drug. Others with "non-life-threatening" cases had to enroll in a computerized random selection process administered by NORD. An estimated 1,600 patients, primarily suffering from West's syndrome and multiple sclerosis who experience episodes of "flare," have been allowed access to HP Acthar Gel each year for the past four years under the limited access program. More than 5,000 additional patients whose physicians requested the drug were denied. The origins of this drug shortage crisis date back to 1996 when Aventis Pharmaceuticals stopped making Acthar for a few months because of manufacturing difficulties. But now, Questcor Pharmaceuticals, Inc. (AMEX: QSC) has signed an agreement with Aventis to acquire the worldwide rights to HP Acthar Gel. Questcor has also reached a manufacturing agreement with Aventis and will gradually move production to an independent manufacturing facility. As a result, HP Acthar Gel is now back in full production and is returning to normal levels of distribution. Questcor began shipments of HP Acthar Gel to wholesalers the last week of September 2001, giving patients in need access to the product. "We are delighted that Questcor is making this critically important product more widely available after this long period of restricted distribution," said Abbey S. Meyers, president of NORD. "We have been working closely with the company over the last several months to ensure that anyone with a need for Acthar Gel is now able to readily receive the product through more traditional channels. Too many people have suffered as a result of limited access to Acthar Gel." Questcor Pharmaceuticals, Inc. is a fully integrated specialty pharmaceutical company that serves the needs of acute and critical care hospitals with its proprietary products. Visit www.questcor.com for more information on the company and its products. If you are a patient with a disorder that can be treated with Acthar, ask your doctor to contact Questcor Pharmaceuticals at (510) 400-0700. For more information about Acthar, including distribution information, please visit www.Acthar.com.
|
|||||
|
http://www.gomailings.com/ |
||||||
| Internet Meetings Medical Newscast Doctors On-the-Net |